Sage Journals: Discover world-class research

Abstract

Addiction impairs human agency; causes medical, behavioral, and social sequelae; and can result in reduced imputability for addiction-related behavior. Harm reduction refers to a variety of interventions implemented to mitigate the harmful sequelae associated with an individual's ongoing substance use. Whereas there is evidence that harm reduction interventions can reduce addiction-related sequelae and potentially save lives, a discussion of the morality of harm reduction raises issues of consequentialism, virtue ethics, cooperation with evil, double effect, counseling the lesser of two evils, tolerance, gradualism, the principle of totality, and scandal. To illustrate the moral considerations relevant to harm reduction, we discuss the case of the medically supervised injecting service that was proposed by the Sisters of Charity Health Service in 1999 in collaboration with the government of New South Wales at St. Vincent's Hospital in the Darlinghurst suburb of Sydney, Australia. We present the previously unpublished conclusions of the Congregation for the Doctrine of the Faith's (CDF) evaluation of that program. The CDF adjudicated that a medically supervised injecting service constitutes “extremely proximate material cooperation” with substance use and its foreseeable adverse effects, and therefore ruled against administering such a program at a Catholic hospital. This decision raises the issue that specific harm reduction interventions can be associated with varying degrees of cooperation with addiction. Drawing from Catholic tradition, we provide guidance that can inform the provision of morally permissible harm reduction interventions.

Keywords

addiction Catholic ethics harm reduction substance use disorder

Get full access to this article

View all access options for this article.

References

Aceijas

2012. “The Ethics in Substitution Treatment and Harm Reduction. An Analytical Review.” Public Health Reviews 34 (1): 1–12. https://doi.org/10.1007/BF03391668 .

Anscombe

G. E. M.

1982. “Medalist’s Address: Action, Intention and ‘Double Effect’.” Proceedings of the American Catholic Philosophical Association 56: 12–25. https://doi.org/10.5840/acpaproc19825611 .

Aquila

S. J.

2023. That They Might Have Life: A Pastoral Letter. Archdiocese of Denver.

Aquinas

Summa Theologiae .

Aristotle. Nicomachean Ethics .

Auza

2016. “Apostolic Nuncio and Permanent Observer of the Holy See to the United Nations United Nations Special Session of the General Assembly on the World Drug Problem.” April 21.

Beauchamp

T. L.

Childress

J. F.

. 2013. Principles of Biomedical Ethics. 8th edition. New York, NY: Oxford University Press.

Benedict XVI. 2006. “Faith, Reason and the University: Memories and Reflections.” Aula Magna of the University of Regensburg, September 12.

Berridge

K. C.

Robinson

T. E.

. 2016. “Liking, Wanting, and the Incentive-Sensitization Theory of Addiction.” American Psychologist 71 (8): 670–679. https://doi.org/10.1037/amp0000059 .

10.

Biancarelli

D. L.

Biello

K. B.

Childs

, et al. 2019. “Strategies Used by People Who Inject Drugs to Avoid Stigma in Healthcare Settings.” Drug and Alcohol Dependence. 198: 80–86. https://doi.org/10.1016/j.drugalcdep.2019.01.037

11.

Blanco

Okuda

Wang

Liu

S. M.

Olfson

. 2014. “Testing the Drug Substitution Switching-Addictions Hypothesis. A Prospective Study in a Nationally Representative Sample.” JAMA Psychiatry 71 (11): 1246–1253. https://doi.org/10.1001/jamapsychiatry.2014.1206

12.

Bogdan

Hatoum

A. S.

Johnson

E. C.

Agrawal

. 2023. “The Genetically Informed Neurobiology of Addiction (GINA) Model.” Nature Reviews Neurosciences 24 (1): 40–57. https://doi.org/10.1038/s41583-022-00656-8

13.

Bozza

Berger

. 2020. “Safe Injection Sites: A Moral Reflection.” Linacre Quarterly 87 (1): 85–93. https://doi.org/10.1177/0024363919861590 .

14.

Bråbäck

Nilsson

Isendahl

Troberg

Brådvik

Håkansson

. 2016. “Malmö Treatment Referral and Intervention Study (MATRIS)—Effective Referral from Syringe Exchange to Treatment for Heroin Dependence: A Pilot Randomized Controlled Trial.” Addiction 111 (5): 866–873. https://doi.org/10.1111/add.13249

15.

Bramness

J. G.

Heiberg

I. H.

Høye

Rossow

. 2023. “Mortality and Alcohol-Related Morbidity in Patients with Delirium Tremens, Alcohol Withdrawal State or Alcohol Dependence in Norway: A Register-Based Prospective Cohort Study.” Addiction 118 (12): 2352–2359. https://doi.org/10.1111/add.16297

16.

Brock

S. L.

2019. “The Specification of Action in St. Thomas: Nonmotivating Conditions in the Object of Intention.” The Thomist: A Speculative Quarterly Review 83 (3): 321–355. https://doi.org/10.1353/tho.2019.0024 .

17.

Burke

2010. Drug Abuse, AIDS and the Lesser Evil; Albany, N.Y., Diocese Defends Needle Exchange, but Some Catholic Scholars Take Exception. The Washington Post, February 13.

18.

Calsyn

D. A.

DeMarco

F. J.

Saxon

A. J.

Sloan

K. L.

Gibbon

K. E.

. 2003. “Evaluation of a Minimal Services Treatment Track for Noncompliant Patients in Opioid Substitution Treatment.” The American Journal of Public Health 93 (7): 1086–1088. https://doi.org/10.2105/ajph.93.7.1086

19.

Canadian Conference of Catholic Bishops. 2017. “Statement on Canada’s Opioid Crisis and Drug Addiction.” Accessed August 21, 2025. https://www.cccb.ca/wp-content/uploads/2017/04/Statement_on_drugs_-_EN.pdf.

20.

Carroll

2025. “The Psychedelic Renaissance: A Catholic Perspective.” Linacre Quarterly 92 (2): 193–220. https://doi.org/10.1177/00243639241274818 .

21.

Cataldo

P. J.

. 2022. “The Principle of the Double Effect as Preserving Integral Goodness: A Brief Historical Overview.” Health Care Ethics USA Summer/Fall: 3–11.

22.

Catechism of the Catholic Church . 1995. New York: Doubleday.

23.

Catholic Health Australia. 2001. “Code of Ethical Standards for Catholic Health and Aged Care Services in Australia.”

24.

Chen

Yang

Chen

Jiang

Zhao

. 2020. “Risky Decision-Making in Individuals with Substance Use Disorder: A Meta-Analysis and Meta-Regression Review.” Psychopharmacology (Berl) 237 (7): 1893–1908. https://doi.org/10.1007/s00213-020-05506-y

25.

Christie

Groarke

Sweet

. 2008. “Virtue Ethics as an Alternative to Deontological and Consequential Reasoning in the Harm Reduction Debate.” The International Journal of Drug Policy 19 (1): 52–58. https://doi.org/10.1016/j.drugpo.2007.11.020 .

26.

Chullikatt

F. A.

2011. “Statement by Archbishop Francis Assisi Chullikatt, Permanent Observer of the Holy See to the United Nations.” New York, NY, June 10.

27.

Clark

P. A.

2009. “Heroin Addiction: An Ethical Evaluation of New York City’s Heroin Manual.” Internet Journal of Health 12 (1). https://ispub.com/IJH/12/1/4549 .

28.

Clifton

Wodak

Gleeson

Fisher

. 1999. “Supervised Injecting Rooms: A Symposium.” Bioethics Outlook 10 (3): 1–16.

29.

Cloud

Granfield

. 2008. “Conceptualizing Recovery Capital: Expansion of a Theoretical Construct.” Substance Use & Misuse 43 (12–13): 1971–1986. https://doi.org/10.1080/10826080802289762 .

30.

Compton

W. M.

Thomas

Y. F.

Stinson

F. S.

Grant

B. F.

. 2007. “Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Drug Abuse and Dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions.” Archives of General Psychiatry 64 (5): 566–576. https://doi.org/10.1001/archpsyc.64.5.566

31.

Congregation for the Doctrine of the Faith. 2010. Note on the Banalization of Sexuality Regarding Certain Interpretations of ‘Light of the World.’

32.

Congregation for the Doctrine of the Faith. 1980. Declaration on Euthanasia .

33.

Connaughton

C. L.

Boerstler

J. J.

. 2021. “Harm Reduction for Intravenous Substance Use: A Moral Analysis of Common Strategies.” The National Catholic Bioethics Quarterly 21 (1): 69–84. https://doi.org/10.5840/ncbq20212118 .

34.

Corrao

Bagnardi

Zambon

La Vecchia

. 2004. “A Meta-Analysis of Alcohol Consumption and the Risk of 15 Diseases.” Preventive Medicine 38 (5): 613–619. https://doi.org/10.1016/j.ypmed.2003.11.027

35.

Cosgrove

1999. Vatican: Nuns and Heroin Don’t Mix. National Catholic Register.

36.

Crawford

A. M.

Pentz

M. A.

Chou

C. P.

Dwyer

H. J.

. 2003. “Parallel Developmental Trajectories of Sensation Seeking and Regular Substance Use in Adolescents.” Psychology of Addictive Behaviors 17 (3): 179–192. https://doi.org/10.1037/0893-164X.17.3.179

37.

Cronin

2001. “Harm Reduction and Drug Abuse.” The Furrow 52 (3): 154–163.

38.

Darke

Larney

Farrell

. 2017. “Yes, People can Die from Opiate Withdrawal.” Addiction 112 (2): 199–200. https://doi.org/10.1111/add.13512 .

39.

Day

C. A.

Salmon

Jauncey

Bartlett

Roxburgh

. 2022. “Twenty-one Years at the Uniting Medically Supervised Injecting Centre, Sydney: Addressing the Remaining Questions.” Medical Journal of Australia 217 (8): 385–387. https://doi.org/10.5694/mja2.51716

40.

Dea

2020. “Toward a Philosophy of Harm Reduction.” Health Care Analysis 28 (4): 302–313. https://doi.org/10.1007/s10728-020-00405-x .

41.

Deak

J. D.

Johnson

E. C.

. 2021. “Genetics of Substance Use Disorders: A Review.” Psychological Medicine 51 (13): 2189–2200. https://doi.org/10.1017/S0033291721000969 .

42.

Dernbach

Matthew.

2025. “Addiction is a Dignity Disorder.” Linacre Quarterly 92 (3): 321–335. https://doi.org/10.1177/00243639241290849 .

43.

Dicastery for the Doctrine of the Faith. 2024. Dignitas Infinita .

44.

Dole

V. P.

Nyswander

M. E.

. 1967. “Heroin Addiction–a Metabolic Disease.” Archives of Internal Medicine 120 (1): 19–24.

45.

Dowell

Ragan

K. R.

Jones

C. M.

Baldwin

G. T.

Chou

. 2022. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022.” MMWR Recommendations and Reports 71 (3): 1–95. https://doi.org/10.15585/mmwr.rr7103a1

46.

Dubowitz

Kim

Black

M. M.

Weisbart

Magder

L. S.

. 2011. “Identifying Children at High Risk for a Child Maltreatment Report.” Child Abuse & Neglect 35 (2): 96–104. https://doi.org/10.1016/j.chiabu.2010.09.003

47.

Duff

2020. “On the Legacy of Normalization.” Addiction 115 (7): 1378–1381. https://doi.org/10.1111/add.15000

48.

Ellis

J. D.

Dunn

K. E.

Huhn

A. S.

. 2024. “Harm Reduction for Opioid Use Disorder: Strategies and Outcome Metrics.” American Journal of Psychiatry 181 (5): 372–380. https://doi.org/10.1176/appi.ajp.20230918 .

49.

Emmanuelli

Desenclos

J. C.

. 2005. “Harm Reduction Interventions, Behaviours and Associated Health Outcomes in France, 1996-2003.” Addiction 100 (11): 1690–1700. https://doi.org/10.1111/j.1360-0443.2005.01271.x .

50.

Erickson

P. G.

1995. “Harm Reduction: What It is and is Not.” Drug and Alcohol Review 14 (3): 283–285. https://doi.org/10.1080/09595239500185361 .

51.

Falfushynska

Rychter

Boshtova

Faidiuk

Kasianchuk

Rzymski

. 2024. “Illicit Drugs in Surface Waters: How to Get Fish Off the Addictive Hook.” Pharmaceuticals (Basel) 17 (4): 537. https://doi.org/10.3390/ph17040537

52.

Fisher

2012. “Cooperation: Should We Ever Collaborate with Wrongdoing?” In Catholic Bioethics for a New Millennium, Chapter 3, 69–98. Cambridge: Cambridge University Press. https://doi.org/10.1017/CBO9780511841866

53.

Flannery

K. L.

2011. “On Counseling the Lesser Evil.” The Thomist: A Speculative Quarterly Review 75 (2): 245–289. https://doi.org/10.1353/tho.2011.0013 .

54.

Flannery

K. L.

2013. “Two Factors in the Analysis of Cooperation in Evil.” The National Catholic Bioethics Quarterly 13 (4): 663–675. https://doi.org/10.5840/ncbq20131349 .

55.

Flannery

K. L.

2019. Cooperation with Evil: Thomistic Tools of Analysis. Washington D.C.: The Catholic University of America Press.

56.

Flannery

K. L.

2021. “Avoiding Illicit Cooperation with Evil: Alphonsus Liguori, Thomas Aquinas, and Contemporary Issues.” The National Catholic Bioethics Quarterly 21 (2): 231–246. https://doi.org/10.5840/ncbq202121224

57.

Flannery

K. L.

Berg

T. V.

2018. “Amoris Laetitia, Pastoral Discernment, and Thomas Aquinas.” Nova et Vetera 16 (1): 81–111. https://doi.org/10.1353/nov.2018.0004

58.

Fleming

D. J

. 2019. “Might We Celebrate A Small Step? Beyond Deculpabilization in Amoris Laetitia.” Irish Theological Quarterly 84 (1): 39–56. https://doi.org/10.1177/0021140018815854

59.

Floris

2025. “What Is the Point of Harm Reduction? A Relational Egalitarian Perspective.” British Journal of Political Science 55: e89. https://doi.org/10.1017/S0007123425000419 .

60.

Francis. 2014. “Address to 31st International Drug Enforcement Conference.” Rome, June 19.

61.

Francis. 2016. Amoris Laetitia .

62.

Furton

E. J.

2024. The Abuse of Toleration. The National Catholic Bioethics Center. https://www.ncbcenter.org/messages-from-presidents/toleration.

63.

Gardiner

2003. “A Virtue Ethics Approach to Moral Dilemmas in Medicine.” Journal of Medical Ethics 29 (5): 297–302. https://doi.org/10.1136/jme.29.5.297 .

64.

Gerra

Maremmani,

Capovani

, et al. 2009. “Long-acting Opioid-Agonists in the Treatment of Heroin Addiction: Why Should We Call Them “Substitution”?” Substance Use & Misuse 44 (5): 663–671. https://doi.org/10.1080/10826080902810251

65.

Giné

C. V.

Vilamala

M. V.

Measham

, et al. 2017. “The Utility of Drug Checking Services as Monitoring Tools and More: A Response to Pirona et al.” International Journal of Drug Policy 45: 46–47. https://doi.org/10.1016/j.drugpo.2017.05.018

66.

Gleeson

1999. “St. Vincent's Withdraws from Supervised Injecting Room.” Bioethics Outlook 10 (4): 1–6.

67.

Granado

2023. “‘Charity Builds Up’ (1 Cor 8:1)—But Which Charity? On Víctor Manuel Fernández’s Theological Proposal.” Communio: International Catholic Review 50 (4): 806–830. https://doi.org/10.1353/cmm.2023.a933254 .

68.

Grant

B. F.

Saha

T. D.

Ruan

W. J.

, et al. 2016. “Epidemiology of DSM-5 Drug Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.” JAMA Psychiatry 73 (1): 39–47. https://doi.org/10.1001/jamapsychiatry.2015.2132

69.

Hagan

McGough

J. P.

Thiede

Hopkins

Duchin

Alexander

E. R.

. 2000. “Reduced Injection Frequency and Increased Entry and Retention in Drug Treatment Associated with Needle-Exchange Participation in Seattle Drug Injectors.” Journal of Substance Abuse Treatment 19 (3): 247–252. https://doi.org/10.1016/s0740-5472(00)00104-5

70.

Hartzler

Cotton

A. J.

Calsyn

D. A.

Guerra

Gignoux

. 2010. “Dissolution of a Harm Reduction Track for Opiate Agonist Treatment: Longitudinal Impact on Treatment Retention, Substance Use and Service Utilization.” International Journal of Drug Policy 21 (1): 82–85. https://doi.org/10.1016/j.drugpo.2009.01.005

71.

Hatzenbuehler

M. L.

Phelan

J. C.

Link

B. G.

. 2013. “Stigma as a Fundamental Cause of Population Health Inequalities.” American Journal of Public Health 103 (5): 813–821. https://doi.org/10.2105/AJPH.2012.301069 .

72.

Hawk

K. F.

Vaca

F. E.

D’Onofrio

. 2015. “Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies.” Yale Journal of Biology and Medicine 88 (3): 235–245.

73.

Hawk

Coulter

R. W. S.

Egan

J. E.

, et al. 2017. “Harm Reduction Principles for Healthcare Settings.” Harm Reduction Journal 14 (1): 70. https://doi.org/10.1186/s12954-017-0196-4

74.

Heather

2020. “The Concept of Akrasia as the Foundation for a Dual Systems Theory of Addiction.” Behavioural Brain Research 390. https://doi.org/10.1016/j.bbr.2020.112666 .

75.

Hendrickson

R. G.

Lin

A. L.

Temple

. 2025. “Pediatric Exposure to Illicit Fentanyl is Associated with Drug Availability in the Community.” Clinical Toxicology (Phila) 63 (2): 115–117. https://doi.org/10.1080/15563650.2024.2438271 .

76.

Henssler

Müller

Carreira

Bschor

Heinz

Baethge

. 2021. “Controlled Drinking-Non-Abstinent Versus Abstinent Treatment Goals in Alcohol use Disorder: A Systematic Review, Meta-Analysis and Meta-Regression.” Addiction 116 (8): 1973–1987. https://doi.org/10.1111/add.15329

77.

Heyman

G. M.

2013. “Addiction and Choice: Theory and New Data.” Frontiers in Psychiatry 4: 31. https://doi.org/10.3389/fpsyt.2013.00031 .

78.

Hoffman

2020. “Kantian Harm Reduction.” Health Care Analysis 28 (4): 335–342. https://doi.org/10.1007/s10728-020-00408-8

79.

Horvat

Roszak

Taylor

B. J.

. 2022. “Is It Harmful? A Thomistic Perspective on Risk Science in Social Welfare.” Journal of Religion and Health 61 (4): 3302–3316. https://doi.org/10.1007/s10943-021-01452-x .

80.

Isman

Giorgi

Ellis

J. D.

Huhn

A. S.

Liu

Curtis

. 2025. “Perceived Stigma and Its Role in Substance Use Disorder Treatment Completion.” American Journal of Drug and Alcohol Abuse 51 (5): 628–638. https://doi.org/10.1080/00952990.2025.2528778

81.

John Paul II. 1992. “The Address of His Holiness John Paul II to Participants in the Sixth International Conference: ‘Drug Addiction and Alcoholism Frustrate the Person's Very Capacity for Community and Self–Giving.’” Dolentium Hominum 19 (1): 7–9.

82.

John Paul II. 1981. Familiaris Consortio .

83.

John Paul II. 1993. Veritatis Splendor .

84.

John Paul II. 1995. Evangelium Vitae .

85.

Johnson

J. A.

Bootman

J. L.

. 1995. “Drug-related Morbidity and Mortality. A Cost-of-Illness Model.” Archives of Internal Medicine 155 (18): 1949–1956.

86.

John XIII. 1963. Pacem in Terris .

87.

Kaczor

2011. “Philosophy and Theology: Notes on Double Effect Reasoning.” The National Catholic Bioethics Quarterly 11 (3): 381–386.

88.

Keane

2003. “Critiques of Harm Reduction, Morality and the Promise of Human Rights.” International Journal of Drug Policy 14 (3): 227–232. https://doi.org/10.1016/S0955-3959(02)00151-2 .

89.

Kellogg

S. H.

2003. “On ‘Gradualism’ and the Building of the Harm Reduction-Abstinence Continuum.” Journal of Substance Abuse Treatment 25 (4): 241–247. https://doi.org/10.1016/s0740-5472(03)00068-0 .

90.

Kelly

1955. “Pope Pius XII and the Principle of Totality.” Theological Studies 16 (3): 373–396. https://doi.org/10.1177/004056395501600302 .

91.

Kendler

K. S.

Ohlsson

Sundquist

. 2017. “Drug Abuse-associated Mortality Across the Lifespan: A Population-based Longitudinal Cohort and Co-relative Analysis.” Social Psychiatry and Psychiatric Epidemiology 52 (7): 877–886. https://doi.org/10.1007/s00127-017-1398-5

92.

Kenny

1993. Aquinas on Mind. New York: Routledge.

93.

Kepple

N. J.

2018. “Does Parental Substance Use Always Engender Risk for Children? Comparing Incidence Rate Ratios of Abusive and Neglectful Behaviors Across Substance Use Behavior Patterns.” Child Abuse & Neglect 76: 44–55. https://doi.org/10.1016/j.chiabu.2017.09.015 .

94.

Kidorf

King

V. L.

Gandotra

Kolodner

Brooner

R. K.

. 2012. “Improving Treatment Enrollment and Re-enrollment Rates of Syringe Exchangers: 12-Month Outcomes.” Drug and Alcohol Dependence 124 (1-2): 162–166. https://doi.org/10.1016/j.drugalcdep.2011.12.008

95.

Kidorf

King

V. L.

Neufeld

Peirce

Kolodner

Brooner

R. K.

. 2009. “Improving Substance Abuse Treatment Enrollment in Community Syringe Exchangers.” Addiction 104 (5): 786–795. https://doi.org/10.1111/j.1360-0443.2009.02560.x

96.

Kimmel

S. D.

Gaeta

J. M.

Hadland

S. E.

Hallett

Marshall

B. D. L.

. 2021. “Principles of Harm Reduction for Young People Who Use Drugs.” Pediatrics 147 (Suppl 2): S240–S248. https://doi.org/10.1542/peds.2020-023523G

97.

King

N. B.

2020. “Harm Reduction: A Misnomer.” Health Care Analysis 28 (4): 324–334. https://doi.org/10.1007/s10728-020-00413-x .

98.

Kockler

N. J.

2007. “The Principle of Double Effect and Proportionate Reason.” Virtual Mentor 9 (5): 369–374. https://doi.org/10.1001/virtualmentor.2007.9.5.pfor2-0705 .

99.

Kolla

B. P.

Oesterle

Gold

Southwick

Rummans

. 2020. “Infectious Diseases Occurring in the Context of Substance Use Disorders: A Concise Review.” Journal of the Neurological Sciences 411: 116719. https://doi.org/10.1016/j.jns.2020.116719

100.

Kordy

Petrich

Read

S. E.

Bitnun

. 2017. “Childhood Exposures to Discarded Needles and Other Objects Potentially Contaminated with Blood-Borne Pathogens in Toronto, Canada.” Paediatrics & Child Health 22 (7): 372–376. https://doi.org/10.1093/pch/pxx110

101.

Krawczyk

Fawole

Yang

Tofighi

. 2021. “Early Innovations in Opioid Use Disorder Treatment and Harm Reduction During the COVID-19 Pandemic: A Scoping Review.” Addiction Science & Clinical Practice 16 (1): 68. https://doi.org/10.1186/s13722-021-00275-1

102.

Krieger

M. S.

Goedel

W. C.

Buxton

J. A.

, et al. 2018. “Use of Rapid Fentanyl Test Strips Among Young Adults Who Use Drugs.” International Journal of Drug Policy 61: 52–58. https://doi.org/10.1016/j.drugpo.2018.09.009

103.

Kuo

Brady

Butler

, et al. 2003. “Feasibility of Referring Drug Users from a Needle Exchange Program into an Addiction Treatment Program: Experience with a Mobile Treatment Van and LAAM Maintenance.” Journal of Substance Abuse Treatment 24 (1): 67–74. https://doi.org/10.1016/s0740-5472(02)00343-4

104.

Kwako

L. E.

Koob

G. F.

. 2017. “Neuroclinical Framework for the Role of Stress in Addiction.” Chronic Stress (Thousand Oaks) 1. https://doi.org/10.1177/2470547017698140 .

105.

Labouvie

Pinsky

. 2001. “Substance Use and Driving: The Coexistence of Risky and Safe Behaviors.” Addiction 96 (3): 473–484. https://doi.org/10.1046/j.1360-0443.2001.96347310.x .

106.

Laslett

A. M.

Room

Dietze

Ferris

. 2012. “Alcohol’s Involvement in Recurrent Child Abuse and Neglect Cases.” Addiction 107 (10): 1786–1793. https://doi.org/10.1111/j.1360-0443.2012.03917.x

107.

Lenton

Single

. 1998. “The Definition of Harm Reduction.” Drug and Alcohol Review 17 (2): 213–219. https://doi.org/10.1080/09595239800187011 .

108.

Leo XIII. 1888. Libertas .

109.

Levinson

Cohen

M. S.

Brady

Duffy

F. D.

. 2001. “To Change or Not to Change: ‘Sounds Like You have a Dilemma.’ Annals of Internal Medicine 135 (5): 386–391. https://doi.org/10.7326/0003-4819-135-5-200109040-00027

110.

Lewis

2017. “Addiction and the Brain: Development, Not Disease.” Neuroethics 10 (1): 7–18. https://doi.org/10.1007/s12152-016-9293-4 .

111.

Lewis

2018. “Brain Change in Addiction as Learning, Not Disease.” New England Journal of Medicine 379 (16): 1551–1560. https://doi.org/10.1056/NEJMra1602872 .

112.

Peterson

Mikosz

C. A.

Luo

. 2023. “Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population.” JAMA Network Open 6 (1): e2252378. https://doi.org/10.1001/jamanetworkopen.2022.52378

113.

Linton

S. L.

Jennings

J. M.

Latkin

C. A.

Gomez

M. B.

Mehta

S. H.

. 2014. “Application of Space-Time Scan Statistics to Describe Geographic and Temporal Clustering of Visible Drug Activity.” Journal of Urban Health 91 (5): 940–956. https://doi.org/10.1007/s11524-014-9890-7

114.

Madah-Amiri

Gjersing

Clausen

. 2019. “Naloxone Distribution and Possession Following a Large-Scale Naloxone Programme.” Addiction 114 (1): 92–100. https://doi.org/10.1111/add.14425 .

115.

Marlatt

G. A.

1996. “Harm Reduction: Come as You are.” Addictive Behaviors 21 (6): 779–788. https://doi.org/10.1016/0306-4603(96)00042-1 .

116.

Marshall

B. D.

Milloy

M. J.

Wood

Montaner

J. S.

Kerr

. 2011. “Reduction in Overdose Mortality After the Opening of North America's First Medically Supervised Safer Injecting Facility: A Retrospective Population-Based Study.” Lancet 377 (9775): 1429–1437. https://doi.org/10.1016/S0140-6736(10)62353-7

117.

Martin

Englander

Calcaterra

S. L.

. 2023. “Things We Do for No Reason^TM: Avoiding Methadone for Opioid Withdrawal.” Journal of Hospital Medicine 18 (11): 1034–1037. https://doi.org/10.1002/jhm.13138 .

118.

McIntyre

R. S.

2023. “Is the Psychedelic Experience an Essential Aspect of the Therapeutic Effect of Serotonergic Psychedelics? Conceptual, Discovery, Development and Implementation Implications for Psilocybin and Related Agents.” Expert Opinion on Drug Safety 22 (10): 885–889. https://doi.org/10.1080/14740338.2023.2253144 .

119.

McKenna

2025. “Delectatio and Recreational Drug Use: Using Aquinas’ Account of Pleasure to Argue that Recreational Drug Use is Immoral.” Linacre Quarterly 92 (1): 61–77. https://doi.org/10.1177/00243639241231595 .

120.

Miller

A. P.

Baranger

D. A. A.

Paul

S. E.

, et al. 2024. “Neuroanatomical Variability and Substance Use Initiation in Late Childhood and Early Adolescence.” JAMA Network Open 7 (12): e2452027. https://doi.org/10.1001/jamanetworkopen.2024.52027

121.

Miller

W. R.

Page

A. C.

. 1991. “Warm Turkey: Other Routes to Abstinence.” Journal of Substance Abuse Treatment 8 (4): 227–232. https://doi.org/10.1016/0740-5472(91)90043-a .

122.

Mullady

1994. “The Moral Act: Object, Circumstances, Intention.” Ethics & Medics 19 (9): 1–2.

123.

Murray

M. A.

2024. “A Theological Justification for the Provision of Medically Supervised Injecting Facilities for People Who Inject Illicit Drugs.” PhD thesis, University of Glasgow. Accessed August 19, 2025. https://theses.gla.ac.uk/84040/2/2023MurrayPhD.pdf.

124.

National Conference of Catholic Bishops. 1989. “Called to Compassion and Responsibility: A Response to the HIV/AIDS Crisis.”

125.

Niccols

2007. “Fetal Alcohol Syndrome and the Developing Socio-emotional Brain.” Brain and Cognition 65 (1): 135–142. https://doi.org/10.1016/j.bandc.2007.02.009 .

126.

O’Hara

G. P.

1945. “Man, the Object of Medicine.” Linacre Quarterly 13 (4): 1–8.

127.

Olding

Ivsins

Mayer

, et al. 2020. “A Low-Barrier and Comprehensive Community-based Harm-Reduction Site in Vancouver, Canada.” American Journal of Public Health 110 (6): 833–835. https://doi.org/10.2105/AJPH.2020.305612

128.

Paul VI. 1964. Lumen Gentium .

129.

Paul VI. 1965a. Dei Verbum .

130.

Paul VI. 1965b. Gaudium et Spes .

131.

Paul VI. 1965c. Nostra Aetate .

132.

Paul VI. 1968. Humanae Vitae .

133.

Peiper

N. C.

Clarke

S. D.

Vincent

L. B.

Ciccarone

Kral

A. H.

Zibbell

J. E.

. 2019. “Fentanyl Test Strips as an Opioid Overdose Prevention Strategy: Findings from a Syringe Services Program in the Southeastern United States.” International Journal of Drug Policy 63: 122–128. https://doi.org/10.1016/j.drugpo.2018.08.007

134.

Peterson

Mikosz

C. A.

Luo

. 2021. “Assessment of Annual Cost of Substance Use Disorder in US Hospitals.” JAMA Network Open 4 (3): e210242. https://doi.org/10.1001/jamanetworkopen.2021.0242

135.

Piazza

N. J.

Vrbka

J. L.

Yeager

R. D.

. 1989. “Telescoping of Alcoholism in Women Alcoholics.” International Journal of the Addictions 24 (1): 19–28. https://doi.org/10.3109/10826088909047272 .

136.

Pickard

2016. Denial in Addiction. Mind & Language 31(3): 277–299. https://doi.org/10.1111/mila.12106

137.

Pius XII. 1953. “Address of the Holy Father Pius XII to the Participants in the Fifth International Congress of Psychotherapy and Clinical Psychology.” April 13. https://www.vatican.va/content/pius-xii/fr/speeches/1953/documents/hf_p-xii_spe_19530413_psicoterapia.html.

138.

Pius XII. 1957. “Address of the Holy Father Pius XII on the Religious and Moral Implications of Analgesia.” February 24. Accessed September 12, 2025. https://www.vatican.va/content/pius-xii/fr/speeches/1957/documents/hf_p-xii_spe_19570224_anestesiologia.html.

139.

Pontifical Council for Health Pastoral Care. 2002. Church: Drugs and Drug Addiction. Vatican City: Libreria Editrice Vaticana.

140.

Pontifical Council for Pastoral Assistance to Health Care Workers. 2021. New Charter for Health Care Workers. Vatican City: Libreria Editrice Vaticana.

141.

Pontifical Council for the Family. 1997. Vademecum for Confessors Concerning Some Aspects of the Morality of Conjugal Life .

142.

Potier

Laprévote

Dubois-Arber

Cottencin

Rolland

. 2014. “Supervised Injection Services: What has been Demonstrated? A Systematic Literature Review.” Drug and Alcohol Dependence 145: 48–68. https://doi.org/10.1016/j.drugalcdep.2014.10.012

143.

Potter

2015. “The Principle of Double Effect in End-of-Life Care.” The National Catholic Bioethics Quarterly 15 (3): 515–529. https://doi.org/10.5840/ncbq201515348 .

144.

Prochaska

J. O.

DiClemente

C. C.

Norcross

J. C.

. 1992. “In Search of How People Change. Applications to Addictive Behaviors.” American Psychologist 47 (9): 1102–1114. https://doi.org/10.1037//0003-066x.47.9.1102 .

145.

Prusak

B. G.

2019. “Start with Safe: Opioids & The Ethics of Harm Reduction.” Commonweal, November 11. https://www.commonwealmagazine.org/start-safe.

146.

Rammohan

Gaines

Scheim

Bayoumi

Werb

. 2024. “Overdose Mortality Incidence and Supervised Consumption Services in Toronto, Canada: An Ecological Study and Spatial Analysis.” Lancet Public Health 9 (2): e79–e87. https://doi.org/10.1016/S2468-2667(23)00300-6

147.

Redish

A. D.

Jensen

Johnson

. 2008. “A Unified Framework for Addiction: Vulnerabilities in the Decision Process.” Behavioral and Brain Sciences 31(4): 415–437; discussion 437-87. https://doi.org/10.1017/S0140525X0800472X

148.

Riley

E. D.

Safaeian

Strathdee

S. A.

Brooner

R. K.

Beilenson

Vlahov

. 2002. “Drug User Treatment Referrals and Entry Among Participants of a Needle Exchange Program.” Substance Use & Misuse 37 (14): 1869–1886. https://doi.org/10.1081/ja-120014088

149.

Ross

E. J.

Graham

D. L.

Money

K. M.

Stanwood

G. D.

. 2015. “Developmental Consequences of Fetal Exposure to Drugs: What We Know and What We Still Must Learn.” Neuropsychopharmacology 40 (1): 61–87. https://doi.org/10.1038/npp.2014.147

150.

Ryrie

I. W.

Dickson

Robbins

Maclean

Climpson

. 1997. “Evaluation of a Low-threshold Clinic for Opiate-Dependent Drug Users.” Journal of Psychiatric and Mental Health Nursing 4 (2): 105–110. https://doi.org/10.1046/j.1365-2850.1997.00038.x

151.

Saxe

Kadushin

Beveridge

, et al. 2001. “The Visibility of Illicit Drugs: Implications for Community-based Drug Control Strategies.” American Journal of Public Health 91 (12): 1987–1994. https://doi.org/10.2105/ajph.91.12.1987

152.

Schaeffer

2012. “Abuse-deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics.” Journal of Medical Toxicology 8 (4): 400–407. https://doi.org/10.1007/s13181-012-0270-y .

153.

Schuckit

M. A.

2006. “Comorbidity Between Substance Use Disorders and Psychiatric Conditions.” Addiction 101 (Suppl 1): 76–88. https://doi.org/10.1111/j.1360-0443.2006.01592.x .

154.

Schulte

M. T.

Hser

Y. I.

. 2014. “Substance Use and Associated Health Conditions Throughout the Lifespan.” Public Health Reviews 35 (2). https://web-beta.archive.org/web/20150206061220/http://www.publichealthreviews.eu/upload/pdf_files/14/00_Schulte_Hser.pdf. https://doi.org/10.1007/BF03391702.

155.

Seeds

J. W.

2012. “Direct Abortion or Legitimate Medical Procedure Double Effect?” Linacre Quarterly 79 (1): 81–87. https://doi.org/10.1179/002436312803571546 .

156.

Sellman

2010. “The 10 Most Important Things Known About Addiction.” Addiction 105 (1): 6–13. https://doi.org/10.1111/j.1360-0443.2009.02673.x .

157.

Shah

R. V.

Shay

Komaromy

. 2025. “Harm Reduction Strategies for People Who Use Drugs.” JAMA 333 (2): 161–162. https://doi.org/10.1001/jama.2024.23605 .

158.

Shih

R. A.

Rodriguez

Parast

, et al. 2019. “Associations Between Young Adult Marijuana Outcomes and Availability of Medical Marijuana Dispensaries and Storefront Signage.” Addiction 114 (12): 2162–2170. https://doi.org/10.1111/add.14711

159.

Simon

Snow

Wakeman

. 2020. “Understanding Why Patients with Substance Use Disorders Leave the Hospital Against Medical Advice: A Qualitative Study.” Substance Abuse 41 (4): 519–525. https://doi.org/10.1080/08897077.2019.1671942 .

160.

Single

1995. “Defining Harm Reduction.” Drug and Alcohol Review 14 (3): 287–290. https://doi.org/10.1080/09595239500185371 .

161.

Sjoquist

B. S.

2023. “Pharmacosophrosyne Revisited: Drug Use and Virtue Ethics.” Linacre Quarterly 90 (3): 290–305. https://doi.org/10.1177/00243639221141223 .

162.

Slaunwhite

Min

J. E.

Palis

, et al. 2024. “Effect of Risk Mitigation Guidance Opioid and Stimulant Dispensations on Mortality and Acute Care Visits During Dual Public Health Emergencies: Retrospective Cohort Study.” BMJ 384: e076336. https://doi.org/10.1136/bmj-2023-076336

163.

Stanley

L. R.

Henry

K. L.

Swaim

R. C.

. 2011. “Physical, Social, and Perceived Availabilities of Alcohol and Last Month Alcohol Use in Rural and Small Urban Communities.” Journal of Youth and Adolescence 40 (9): 1203–1214. https://doi.org/10.1007/s10964-010-9556-z .

164.

Stith

S. M.

Liu

Davies

L. C.

, et al. 2009. “Risk Factors in Child Maltreatment: A Meta-analytic Review of the Literature.” Aggression and Violent Behavior 14 (1): 13–29. https://doi.org/10.1016/j.avb.2006.03.006

165.

Stoljar

2020. “Disgust or Dignity? The Moral Basis of Harm Reduction.” Health Care Analysis 28 (4): 343–351. https://doi.org/10.1007/s10728-020-00412-y .

166.

Strain

E. C.

2022. “The Defining Characteristic of Substance Use Disorders.” Drug and Alcohol Dependence 230: 109207. https://doi.org/10.1016/j.drugalcdep.2021.109207 .

167.

Strathdee

S. A.

Ricketts

E. P.

Huettner

, et al. 2006. “Facilitating Entry into Drug Treatment Among Injection Drug Users Referred from a Needle Exchange Program: Results from a Community-based Behavioral Intervention Trial.” Drug and Alcohol Dependence 83 (3): 225–232. https://doi.org/10.1016/j.drugalcdep.2005.11.015

168.

Substance Abuse and Mental Health Services Administration. 2024. Accessed August 21, 2025. https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.pdf.

169.

Sullivan

Austriaco

. 2016. “A Virtue Analysis of Recreational Marijuana Use.” Linacre Quarterly 83 (2): 158–173. https://doi.org/10.1080/00243639.2015.1125083 .

170.

Sulmasy

D. P.

2012. “Catholic Participation in Needle- and Syringe-Exchange Programs for Injection-Drug Users: An Ethical Analysis.” Theological Studies 73 (2): 422–442. https://doi.org/10.1177/004056391207300207 .

171.

Sussman

Forster

Grigsby

. 2015. “First Things First: What is the First Thing?” Substance Use & Misuse 50 (8–9): 1015–1019. https://doi.org/10.3109/10826084.2015.1007693 .

172.

Sznitman

S. R.

Taubman

D. S.

. 2016. “Drug Use Normalization: A Systematic and Critical Mixed-Methods Review.” Journal of Studies on Alcohol and Drugs 77 (5): 700–709. https://doi.org/10.15288/jsad.2016.77.700 .

173.

Taylor

J. L.

Johnson

Cruz

Gray

J. R.

Schiff

Bagley

S. M.

. 2021. “Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings: Harm Reduction in Outpatient Addiction Treatment.” Journal of General Internal Medicine 36 (12): 3810–3819. https://doi.org/10.1007/s11606-021-06904-4

174.

The National Catholic Bioethics Center. 2013. “Cooperation with Moral Evil.” Accessed August 20, 2025. https://static1.squarespace.com/static/5e3ada1a6a2e8d6a131d1dcd/t/5ed65fe1acf7c915f772f786/1591107554407/NCBCsummFAQ_2013_Cooperation.pdf.

175.

Tilhou

A. S.

Birstler

Baltes

, et al. 2022. “Characteristics and Context of Fentanyl Test Strip Use Among Syringe Service Clients in Southern Wisconsin.” Harm Reduction Journal 19 (1): 142. https://doi.org/10.1186/s12954-022-00720-7

176.

Tilhou

A. S.

Zaborek

Baltes

Salisbury-Afshar

Malicki

Brown

. 2023. “Differences in Drug Use Behaviors that Impact Overdose Risk Among Individuals Who Do and Do Not Use Fentanyl Test Strips for Drug Checking.” Harm Reduction Journal 20 (1): 41. https://doi.org/10.1186/s12954-023-00767-0

177.

Tsai

A. C.

Kiang

M. V.

Barnett

M. L.

, et al. 2019. “Stigma as a Fundamental Hindrance to the United States Opioid Overdose Crisis Response.” PLoS Medicine 16 (11): e1002969. https://doi.org/10.1371/journal.pmed.1002969

178.

Tse

W. C.

Djordjevic

Borja

, et al. 2022. “Does Naloxone Provision Lead to Increased Substance Use? A Systematic Review to Assess If There is Evidence of a ‘Moral Hazard’ Associated with Naloxone Supply.” International Journal of Drug Policy 100: 103513. https://doi.org/10.1016/j.drugpo.2021.103513

179.

United States Conference of Catholic Bishops. 2018. Ethical and Religious Directives for Catholic Health Care Services, Sixth Edition. Washington, DC.

180.

Van Den Berg

Smit

Van Brussel

Coutinho

Prins

, and Amsterdam Cohort. 2007. “Full Participation in Harm Reduction Programmes is Associated with Decreased Risk for Human Immunodeficiency Virus and Hepatitis C Virus: Evidence from the Amsterdam Cohort Studies Among Drug Users.” Addiction 102 (9): 1454–1462. https://doi.org/10.1111/j.1360-0443.2007.01912.x

181.

Vickers-Smith

R. A.

Gelberg

K. H.

Childerhose

J. E.

, et al. 2025. “Fentanyl Test Strip Use and Overdose Risk Reduction Behaviors Among People Who Use Drugs.” JAMA Network Open 8 (5): e2510077. https://doi.org/10.1001/jamanetworkopen.2025.10077

182.

Volkow

N. D.

Koob

G. F.

McLellan

A. T.

. 2016. “Neurobiologic Advances from the Brain Disease Model of Addiction.” New England Journal of Medicine 374 (4): 363–371. https://doi.org/10.1056/NEJMra1511480 .

183.

Wagner

F. A.

Anthony

J. C.

. 2002. “Into the World of Illegal Drug Use: Exposure Opportunity and Other Mechanisms Linking the Use of Alcohol, Tobacco, Marijuana, and Cocaine.” American Journal of Epidemiology 155 (10): 918–925. https://doi.org/10.1093/aje/155.10.918 .

184.

Walker

M. J.

2025. “A Proportionality Approach to the Ethics of Drug Policy.” International Journal of Drug Policy 142: 104861. https://doi.org/10.1016/j.drugpo.2025.104861 .

185.

Wallace

. 2011. “Theory of 12-Step-oriented Treatment.” In Treating Substance Abuse: Theory and Technique, 3rd ed., edited by Walters

S. T.

Rotgers

, 167–190. New York, NY: Guilford Publications.

186.

Walley

A. Y.

Xuan

Hackman

H. H.

, et al. 2013. “Opioid Overdose Rates and Implementation of Overdose Education and Nasal Naloxone Distribution in Massachusetts: Interrupted Time Series Analysis.” BMJ 346: f174. https://doi.org/10.1136/bmj.f174

187.

Watts

B. V.

Gottlieb

D. J.

Riblet

N. B.

Gui

Shiner

. 2022. “Association of Medication Treatment for Opioid Use Disorder with Suicide Mortality.” American Journal of Psychiatry 179 (4): 298–304. https://doi.org/10.1176/appi.ajp.2021.21070700

188.

Wertz

J. M.

Sayette

M. A.

. 2001. “A Review of the Effects of Perceived Drug Use Opportunity of Self-Reported Urge.” Experimental and Clinical Psychopharmacology 9 (1): 3–13. https://doi.org/10.1037/1064-1297.9.1.3 .

189.

Windle

2010. “A Multilevel Developmental Contextual Approach to Substance Use and Addiction.” Biosocieties 5: 124–136. https://doi.org/10.1057/biosoc.2009.9 .

190.

Witkiewitz

Wilson

A. D.

Roos

C. R.

, et al. 2021. “Can Individuals with Alcohol Use Disorder Sustain Non-abstinent Recovery? Non-abstinent Outcomes 10 Years After Alcohol Use Disorder Treatment.” Journal of Addiction Medicine 15 (4): 303–310. https://doi.org/10.1097/ADM.0000000000000760

191.

Zweben

J. E.

Sorensen

J. L.

Shingle

Blazes

C. K.

. 2021. “Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.” Journal of Addiction Medicine 15 (6): 454–460. https://doi.org/10.1097/ADM.0000000000000789

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

3.47 MB

Assessing the Morality of Harm Reduction Interventions in Substance Use Treatment

Abstract

Keywords

Get full access to this article

References

Supplementary Material